Kornimate/medical-research-clean huggingface dataset:
the evaluation of optimal observation period for neurological recovery in post-arrest survivors

Conditions: Cardiology

Summary: to explore whether the patient's neurological function recovery period is sufficient after successful emergency resuscitation recommended by the current guidelines

the research team will collect patient data after successful emergency resuscitation after cardiac arrest in the emergency room of national taiwan university hospital, and will collect and analyze the relationship between the time for patients to regain consciousness and drug use, hemodynamic changes, and neurological examination results after resuscitation. to explore whether the patient population needs to extend the observation time of neurological function after a certain cpr emergency treatment, and allow the patient to have a longer observation period to regain consciousness.

Eligibility criteria:
inclusion criteria: * patients with non-traumatic cardiac arrest in the emergency room of national taiwan university hospital (including pre-hospital cardiac arrest and in-hospital cardiac arrest) after successful emergency resuscitation exclusion criteria: * under 20 years old * pregnant women * those who have not been admitted to the intensive care unit * unconsciousness before the heartbeat stops * a clear consciousness after successful first aid resuscitation

Keywords: cardiac arrest post-cardiac arrest syndrome neurological outcome
efficacy and safety of the association drugs in patients with allergic dermatitis

Conditions: Dermatitis

Summary: considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. therefore it is expected that the association promotes results significantly superior to dexamethasone alone.


Eligibility criteria:
inclusion criteria: * patients who sign the deed of consent (ic) in two ways, by his own free will, agreeing with all study procedures; * patients older than 18 years, any ethnicity, class or social group, regardless of sex; * patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as: * atopic dermatitis, * prurigo, * primary contact dermatitis or allergic * urticaria, * pharmacodermic, * allergic vasculitis, * dyshidrosis, exclusion criteria: * patients being treated with antibiotics; * participation in clinical trials in the 12 months preceding the survey; * current treatment with immunosuppressants (eg, cyclosporine or methotrexate); * current treatment with phototherapy (uva, uvb, puva and lasers); * use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion; * topical treatments at the site of acne in the 15 days preceding the visit of inclusion; * presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion; * presence of secondary infections at the site of treatment, diagnosed clinically; * presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and buckley's syndrome wiskott-aldrich; * pregnant or lactating women; * chronic alcoholism; * patients with a history of hypersensitivity to any component of the formulas of the products under investigation; * any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study; * allergic dermatosis of moderate or severe that, according to the investigator, is not justified topical.

Keywords: allergic dermatitis
safety and efficacy study of l-fmau in chronic hbv patients of l-fmau-201 placebo group

Conditions: Hepatitis B

Summary: the purpose of this study is to evaluate the safety and antiviral activity of clevudine 30 mg qd for treatment of longer period (24 weeks) in patients chronically infected with hbv.


Eligibility criteria:
inclusion criteria: 1. patients who received placebo in l-fmau-201 study 2. female of childbearing potential with a negative serum (beta-hcg) pregnancy test within 14 days of starting therapy. 3. patients who were able to give written informed consent prior to study start and to comply with the study requirements. 4. patients who met the following criteria after completion of the week 48 visit were to have additional follow-up visits at weeks 54 and 60: 1)had received no additional therapy since completion of 24-week treatment of clevudine and 2)experienced a \>= 1 log10 decrease from baseline in hbv dna at week 48 exclusion criteria: 1. patient with hbeag seroconverted to anti-hbe at the last 2 consecutive visits (one month apart) in l-fmau-201 study. 2. patient who was currently receiving antiviral, immunomodulatory or corticosteroid therapy. 3. patient who was treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for hbv infection after cessation of treatment in l-fmau-201 study. 4. patient who had a history of ascites, variceal hemorrhage or hepatic encephalopathy. 5. patient who was co-infected with hcv, hdv or hiv. 6. patient with clinical evidence of cirrhosis or hepatocellular carcinoma (®-fetoprotein)evaluation was based on alpha-fetoprotein primarily. if alpha-fetoprotein level was suggestive of cirrhosis or hepatocellular carcinoma, confirmation was made with ultrasonography etc. 7. patient who was pregnant or breast-feeding. 8. patient who was unwilling to use an "effective" method of contraception during treatment period and for up to 3 months after cessation of therapy. for males, condoms should be used. females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., iud, barrier methods with supermicide or abstinence) 9. patient who had a clinically relevant history of abuse of alcohol or drugs. 10. patient who had a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease. 11. patient who had creatinine clearance less than 60ml/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dl\]) \[note: multiply estimates by 0.85 for women\]
using travelan to boost immune response in vitro to covid-19

Conditions: Covid19

Summary: the gut immune system was shown as an effective target for inducing systemic immune signals against viruses. oral administration of travelan, an over the counter product which contains hyperimmune bovine colostrum was shown in preclinical studies to augment the anti-viral immune towards several strains of influenza viruses (rna viruses). this study will evaluate the option that trevalan may help improve the immune system reaction when introduced to covid-19 proteins in-vitro. 5 healthy volunteers will receive a treatment regimen of 5 days with trevalan. before and after treatment, blood samples will be taken in order to test immune response towards viral proteins of the covid-19 virus in vitro by measuring the number of t cell clone secreting ifnγ against viral antigens.


Eligibility criteria:
inclusion criteria: 1. adult healthy volunteers aged 18 years old and above. 2. no history of drug or alcohol abuse. 3. females of childbearing potential must be non-pregnant (as determined by a serum pregnancy test at screening and again, prior to each dosing session) and agree to use adequate contraceptive means throughout the study. 4. patients must be able to adhere to the visit schedule and protocol requirements and be available to complete the study. 5. patients must satisfy a medical examiner about their fitness to participate in the study. 6. patients must provide written informed consent to participate in the study exclusion criteria: 1. acute illness resulting in emergency department (ed) evaluation or hospitalization in the last 6 month or any acute illness in the last month before enrollment 2. patients with evidence of other serious infectious, malignant, autoimmune, kidney, hepatic, or other non-cardiac systemic disease. 3. chronic drug therapy of any sort 4. known allergy to milk 5. over-the-counter drugs, including herbal medications, and prescription drugs (other than those listed above) are not allowed for 4 weeks prior to and throughout the duration of the study 6. participation in another clinical trial within 30 days prior to intervention. 7. patients with an inability to communicate well with the pi and staff (i.e., language problem, poor mental development or impaired cerebral function). 8. patients who will be unavailable for the duration of the trial, are likely to be noncompliant with the protocol, or who are felt to be unsuitable by the pi for any other reason. 9. known substance abuse, including inhaled or injected drugs in the year prior to screening

Keywords: hyperimmune colostrum
clomiphene citrate in infertile men with idiopathic oligoasthenozoospermia

Conditions: Infertility, Male

Summary: the goal of this clinical trial is to learn if drug clomiphene citrate improves sperm parameters in infertile men with idiopathic oligoasthenozoospermia. it will also learn about the safety of clomiphene citrate. the main questions it aims to answer are: * does drug clomiphene citrate change sperm count and motility in infertile men with idiopathic oligoasthenozoospermia? * what medical problems do participants have when taking drug clomiphene citrate? researchers will compare drug clomiphene citrate to a placebo (a look-alike substance that contains no drug) to see if drug clomiphene citrate works to treat idiopathic oligoasthenozoospermia.


Eligibility criteria:
inclusion criteria: * infertile men * idiopathic oligoasthenozoospermia (serum fsh and serum lh range was 2-7 iu/ml and serum testosterone level was \>300 ng/dl) exclusion criteria: * azoospermia * body mass index \ 30 kg/m2 * any abnormality on genital examination and scrotal sonogram * history of genital diseases \& genital surgery * medical and endocrine disorders like uncontrolled diabetes mellitus, severe kidney disease and liver insufficiency * psycho-sexual abnormalities * antioxidant supplements in previous 3 months * smoking, drug, alcohol or substance abuse * history of chemotherapy or radiotherapy * presence of any gross female factor abnormality

Keywords: male infertility oligoasthenozoospermia testosterone clomiphene citrate
tofacitinib plus hydroxycloroquine vs hydroxycloroquine in patients with covid-19 interstitial pneumonia

Conditions: Pneumonitis, Interstitial; COVID-19

Summary: multifocal interstitial pneumonia represents the most common cause of admission in intensive care units and death in sars-cov2 infections. in our hospital, similarly to what reported in literature, up to 25% of admitted patients with pneumonitis requires mechanical ventilation or oro-tracheal intubation within 5-10 days. no established treatment is available for this condition. preliminary evidence is accumulating about the efficacy of an aggressive treatment of the corona virus-induced inflammation and, in particular, investigators believe that blocking jak1 is clinically rewarding in down-regulating il-6 driven inflammation in patients with corona-virus infection. thus, investigators designed a randomized controlled trial to test the hypothesis that adding tofacitinib to the standard treatment in the early phase of covid related pneumonitis could prevent the development of severe respiratory failure needing mechanical ventilation.


Eligibility criteria:
inclusion criteria: * sars-cov2 infection diagnosed by rt-pcr * ct-scan confirmed interstitial pneumonia * hospital admission from less than 24h * p/f ratio \>150 mmhg * written informed consent exclusion criteria: * age \ 65 * patients in mechanical ventilation at time of admission * severe hearth failure (nyha 3 or 4) * qtc \> 470 ms or \>500 ms in wide qrs patients * severe history of chronic ischemic heart disease, defined as history of major adverse cardiovascular event and/or recent (one year) revascularization. * history of recurrent deep venous thrombosis and pulmonary embolism or established thrombophilic conditions (e.g. history of anti-phospholipid antibodies, ...) * active bacterial or fungal infection * hematological cancer * metastatic or intractable cancer * pre-existent neurodegenerative disease * severe hepatic impairment, * history of acute diverticular disease or intestinal perforation * hbsag positive and/or hbv-dna positive patients * severe renal failure (creatinine clearance \<30ml/h) * active herpes zoster infection * patients with active or latent tb * severe anemia (hb\<9g/dl) * lymphocyte count below 750/mcl * neutrophil count below 1000/mcl * platelet count below 50000/mcl * pregnancy or lactation * history of intolerance to the experimental drugs or excipients * degenerative maculopathy or other relevant retinal disease * inability to give informed consent (severe transitory or permanent mental impairment, incapacitation)
prognostic study of via dynamic change of pca3 mrna in drainage fluid after radical prostatectomy

Conditions: Prostatic Neoplasms; Exosomes

Summary: this study investigates the prognostic value of dynamic changes in pca3 mrna levels found in the abdominal cavity drainage fluid after radical prostatectomy. prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. while psa levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of pca3 mrna levels in the prognosis of prostate cancer. the findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.

this study examines the prognostic significance of pca3 mrna levels in the drainage fluid collected from the abdominal cavity following radical prostatectomy, a common surgical treatment for prostate cancer. psa is widely used as a biomarker for prostate cancer diagnosis, treatment response, and recurrence monitoring in the blood. however, this research seeks to explore the prognostic value of pca3 mrna in the drainage fluid. the study involves continuous monitoring of pca3 mrna levels in the drainage fluid after radical prostatectomy, with the hypothesis that dynamic changes in these levels could serve as an early warning system for potential tumor recurrence, residual disease, or metastasis. the research will correlate these fluid pca3 mrna levels with patient outcomes, recurrence rates, and other clinical factors to determine their predictive value. by investigating this novel source of pca3 mrna monitoring, the study aims to reduce invasive tests, enhance post-operative surveillance, and improve early detection of disease recurrence for prostate cancer patients. this research could contribute to refining post-surgical care protocols, offering a new tool for predict long-term outcomes for individuals undergoing radical prostatectomy.

Eligibility criteria:
inclusion criteria: •prostate cancer patients treated with radical prostatectomy exclusion criteria: * 1. received neoadjuvant endocrine/chemotherapy before surgery; * 2. urine leakage after surgery (positive creatinine test of drainage fluid).
open non-comparative study to evaluate administration of a new nutraceutical

Conditions: Sleep Disorder

Summary: the research hypothesis for the present pilot study in a special care setting is that in a population suffering of mild and recent sleep disorders the pre-sleep arousal measured by the pre-sleep arousal scale (psas) after 30 days of oral administration with a nutraceutical composed of hawthorn, lavender and hop (sonidor®) shall significantly improve in comparison with the baseline condition.

sonidor® was developed as a nutraceutical composed of hawthorn, lavender and hop inducing sleep and relaxation in subjects with mild sleep disturbances. in addition, the sonidor® innovative three-layer-tablet formulation should allow the active components to be released with different speeds into the gastrointestinal tract exerting a synergistic action to induce sleep-promoting effects. primary objective is to have a preliminary evaluation of the efficacy of sonidor® in subjects affected by persistent mild sleep disorders (difficulty in initiating sleep for at least 1 month and reduced quality of sleeping) to whom in special care setting have been suggested sleep hygiene guidelines and administered the tested nutraceutical for one month.

Eligibility criteria:
inclusion criteria: 1. men and women, aged 18 to 70 years with persistent, recent (at least 1 month) and mild sleep disorders related to pre-sleep arousal and reduced quality of sleeping; 2. psas at baseline between 16 and 24; 3. isi at baseline ≥ 12; 4. able to communicate adequately with the investigator and to comply with the requirements for the entire study; 5. capable of and freely willing to provide written informed consent prior to participating in the study; exclusion criteria: l. subjects with morningness-eveningness questionnaire self-assessment (meqsa) values between 16 and 41; 2. pregnancy and/or breast-feeding; 3. subjects assuming beta blockers, hypnotic or sedative drugs or other nutraceuticals; 4. psychosis, schizophrenia, mania, depressive disorders, history of suicide attempt, or suicidal ideation, or any other psychiatric illness (with the exception of intermittent anxiety); 5. known intolerance to the tested product or at one of the ingredients (hawthorn, lavender or hop); 6. drug or alcohol abuse within 12 months of day 0; 7. all clinical conditions that, at the evaluation of the investigator, can be referred to as secondary insomnia; 8. participation in an interventional clinical study or administration of any investigational agents in the previous 30 days; 9. presence of any clinically significant medical condition judged by the investigator to preclude the subject's inclusion in the study;
vitamin d oral gel for prevention of radiation induced oral mucositis

Conditions: Oral Mucositis Due to Radiation

Summary: the main aim of this study was to evaluate clinically the effect of topical oral vitamin d gel in comparison to conventional therapy in prevention of radiation - induced oral mucositis

the study was designed as randomized, controlled, clinical trial. patients who were undergoing to receive radiotherapy were divided into three groups: group i: was given conventional treatment.group ii : was given topical oral gel of vitamin d. group iii: was given topical oral gel of vitamin d in combination with the conventional treatment. all patients were clinically evaluated at the start the radiotherapy, three weeks and six weeks later for pain and oral mucositis severity.

Eligibility criteria:
inclusion criteria: * patients who are going to receive radiotherapy as a treatment of head and neck cancer either as postoperative (adjuvant) therapy or definitive therapy. * patients whose radiotherapy treatment planned dose is 50 gy or above. * patients receiving radiotherapy alone or receiving concomitant cisplatin (or carboplatin) with radiotherapy. exclusion criteria: * patients under anticoagulants such as warfarin, heparin, or aspirin. * patients whose radiotherapy treatment planned dose is lower than 50 gy. * patients suffering from any uncontrolled systemic diseases (such as diabetes, cardiovascular, liver disorder, renal dysfunction) * patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure. * hyper-calcemic patients. * smokers.

Keywords: vitamin d topical oral gel
haic combined with lenvatinib and pd-1 inhibitor in infiltrative hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Lenvatinib; PD-1 Inhibitor; Hepatic Arterial Infusion Chemotherapy

Summary: hepatic arterial infusion chemotherapy (haic) plus lenvatinib and programmed cell death protein-1 (pd-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (hcc). however, the evidence for infiltrative is limited. in this study, we aimed to describe the efficacy and safety of lenvatinib and pd-1 inhibitor with haic plus lenvatinib for infiltrative hcc.

this study is a multicenter, observational real-world study to explore the efficacy, safety of lenvatinib and pd-1 inhibitor with haic in advanced infiltrative hepatocellular carcinoma. this study focused on the management of locoregional therapy combined with lenvatinib and pd-1 inhibitor. this study will create a database that will provide clinical parameters and outcomes of patients undergoing hiac combined lenvatinib and pd-1 inhibitor as standard of care in hopes of answering key clinical questions.

Eligibility criteria:
inclusion criteria: 1. primary infiltrative hcc according to mri or ct imaging characteristics. 2. child-pugh class a or b, and eastern cooperative oncology group performance status (ecog ps) of 0 or 1. 3. lenvatinib as initial treatment. 4. patients received haic and pd-1 inhibitor in haic+len+pd-1 group, patients received lenvatinib alone in len group. 5. no history of other malignancies. 6. no tumor thrombus in the atrium or vena cava. exclusion criteria: 1. hcc with tumor capsule. 2. under 18 years or over 75 years. 3. tace as initial treatment. 4. sorafenib or other systemic therapy with or without pd-1 inhibitor following haic. 5. incomplete tumor imaging data. 6. lost to follow-up after treatment within three months.

Keywords: hepatic arterial infusion chemotherapy tislelizumab toripalimab sintilimab camrelizumab lenvatinib
usability of cognitive improvement software in cognitively impaired patients: pilot study

Conditions: Mild Cognitive Impairment

Summary: usability study of software application that provide digitized cognitive intervention therapy for cognitively impaired patients.


Eligibility criteria:
inclusion criteria: * male and female patients, 55\~85 years * adequate vision, hearing and speaking for neuropsychological testing * no difficulty in using mobile application using smartphone * patients with subjective memory complaints, confirmed by informants * cognitive impairment of sd 1 or greater from the age-adjusted normal range in memory domain in cerad-np battery * global cdr 0.5 \~ 1 * korean speaker * have an identified trial partner * all subjects signed written consent exclusion criteria: * those unable to provide consent * history of transient ischemic attack, stroke, brain tumor * history of diagnosis of major depression * symptoms that may interfere with the subject's testing procedure * cerebral hemorrhage * central nervous system infections * prohibited concomitant medication * known or suspected history of drug or alcohol abuse